Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study

Biomarkers for detection and surveillance of bladder cancer

(2016) Lorne I. Budman et al.   CUAJ-Canadian Urological Association Journal

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

(2014) G Mowatt et al.   HEALTH TECHNOLOGY ASSESSMENT

The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines

(2011) Beate Pesch et al.   BJU INTERNATIONAL

The effect of age and gender on bladder cancer: a critical review of the literature

(2009) Shahrokh F. Shariat et al.   BJU INTERNATIONAL

EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

(2008) Marko Babjuk et al.   EUROPEAN UROLOGY

A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer:the prognostic value of false-positive results

(2003) V. Poulakis et al.   BJU INTERNATIONAL